Journal of Cancer Research and Clinical Oncology

, Volume 135, Issue 3, pp 387–393

Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines

  • Jens Wagenblast
  • Mehran Baghi
  • Christoph Arnoldner
  • Sotirios Bisdas
  • Wolfgang Gstöttner
  • Hanns Ackermann
  • Angelika May
  • Markus Hambek
  • Rainald Knecht
Original Paper

Abstract

Purpose

Proteasome inhibition has been shown to be effective in multiple myeloma and solid tumor models. In this in vitro study, we investigated the antitumor effect of bortezomib (Velcade®) in combination with cetuximab in squamous cell carcinoma cell lines (SCC).

Methods

Dose-escalation studies were performed in five squamous cell carcinoma cell lines using bortezomib or cetuximab alone or in combination. Cell survival and growth inhibition were measured quantitatively using an MTT and LDH assay.

Results

Bortezomib alone showed a significant antiproliferative activity in all SCC cell lines (P < 0.042), and the activity was further significantly enhanced by the addition of cetuximab (P < 0.043).

Conclusions

Our results indicate that cetuximab increases the cytotoxic activity of bortezomib in SCC cell lines. Combination therapy of SCC with bortezomib and cetuximab might be less toxic than conventional drug regimens used in the treatment of these tumors.

Keywords

Bortezomib Cetuximab Squamous cell carcinoma cell lines Growth inhibition Cytotoxicity 

References

  1. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD et al (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59:2615–2622PubMedGoogle Scholar
  2. An J, Rettig MB (2007) Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib. Mol Cancer Ther 6:61–69. doi:10.1158/1535-7163.MCT-06-0255 PubMedCrossRefGoogle Scholar
  3. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578. doi:10.1056/NEJMoa053422 PubMedCrossRefGoogle Scholar
  4. Browman GP, Cronin L (1994) Standard chemotherapy in squamous cell head and neck cancer: what we have learned from randomized trials. Semin Oncol 21:311–319PubMedGoogle Scholar
  5. Burtness B (2005) The role of cetuximab in the treatment of squamous cell cancer of the head and neck. Expert Opin Biol Ther 5:1085–1093. doi:10.1517/14712598.5.8.1085 PubMedCrossRefGoogle Scholar
  6. Cusack JC (2003) Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat Rev 29(Suppl 1):21–31. doi:10.1016/S0305-7372(03)00079-3 PubMedCrossRefGoogle Scholar
  7. Dubey S, Schiller JH (2005) Three emerging new drugs for NSCLC: pemetrexed, bortezomib, and cetuximab. Oncologist 10:282–291. doi:10.1634/theoncologist.10-4-282 PubMedCrossRefGoogle Scholar
  8. Fischel JL, Formento P, Milano G (2005) Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab) Impact on cell growth and molecular factors. Br J Cancer 92:1063–1068. doi:10.1038/sj.bjc.6602428 PubMedCrossRefGoogle Scholar
  9. Fribley A, Zeng Q, Wang CY (2004) Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 24:9695–9704. doi:10.1128/MCB.24.22.9695-9704.2004 PubMedCrossRefGoogle Scholar
  10. Fribley AM, Evenchik B, Zeng Q, Park BK, Guan JY, Zhang H et al (2006) Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa. J Biol Chem 281:31440–31447. doi:10.1074/jbc.M604356200 PubMedCrossRefGoogle Scholar
  11. Hanawa M, Suzuki S, Dobashi Y, Yamane T, Kono K, Enomoto N et al (2006) EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer 118:1173–1180. doi:10.1002/ijc.21454 PubMedCrossRefGoogle Scholar
  12. Harding J, Burtness B (2005) Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc) 41:107–127. doi:10.1358/dot.2005.41.2.882662 CrossRefGoogle Scholar
  13. Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM (2004) Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 64:5355–5362. doi:10.1158/0008-5472.CAN-04-0562 PubMedCrossRefGoogle Scholar
  14. Ling YH, Liebes L, Ng B, Buckley M, Elliott PJ, Adams J et al (2002) PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther 1:841–849PubMedGoogle Scholar
  15. Ling YH, Liebes L, Jiang JD, Holland JF, Elliott PJ, Adams J et al (2003a) Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 9:1145–1154PubMedGoogle Scholar
  16. Ling YH, Liebes L, Zou Y, Perez-Soler R (2003b) Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 278:33714–33723. doi:10.1074/jbc.M302559200 PubMedCrossRefGoogle Scholar
  17. Lorch JH, Thomas TO, Schmoll HJ (2007) Bortezomib inhibits cell–cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer. Cancer Res 67:727–734. doi:10.1158/0008-5472.CAN-06-2162 PubMedCrossRefGoogle Scholar
  18. Marshall CJ (1995) Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80:179–185. doi:10.1016/0092-8674(95)90401-8 PubMedCrossRefGoogle Scholar
  19. Mortenson MM, Schlieman MG, Virudachalam S, Bold RJ (2004) Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line. Cancer Chemother Pharmacol 54:343–353. doi:10.1007/s00280-004-0811-4 PubMedCrossRefGoogle Scholar
  20. Pignon JP, Bourhis J, Domenge C, Designe L (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355:949–955PubMedGoogle Scholar
  21. Reuter CW, Morgan MA, Eckardt A (2007) Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. Br J Cancer 96:408–416. doi:10.1038/sj.bjc.6603566 PubMedCrossRefGoogle Scholar
  22. Rogers SJ, Harrington KJ, Rhys-Evans P, O-Charoenrat P, Eccles SA (2005) Biological significance of c-erbB family oncogenes in head and neck cancer. Cancer Metastasis Rev 24:47–69. doi:10.1007/s10555-005-5047-1 PubMedCrossRefGoogle Scholar
  23. Tahara E, Sumiyoshi H, Hata J, Yasui W, Taniyama K, Hayashi T et al (1986) Human epidermal growth factor in gastric carcinoma as a biologic marker of high malignancy. Jpn J Cancer Res 77:145–152PubMedGoogle Scholar
  24. Thompson JE, Thompson CB (2004) Putting the rap on Akt. J Clin Oncol 22:4217–4226. doi:10.1200/JCO.2004.01.103 PubMedCrossRefGoogle Scholar
  25. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F et al (2007) Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25:2171–2177. doi:10.1200/JCO.2006.06.7447 PubMedCrossRefGoogle Scholar
  26. Wagenblast J, Hambek M, Baghi M, Gstottner W, Strebhardt K, Ackermann H et al (2008a) Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines. J Cancer Res Clin Oncol 134:323–330. doi:10.1007/s00432-007-0287-9 PubMedCrossRefGoogle Scholar
  27. Wagenblast J, Hambek M, Baghi M, Knecht R (2008b) Effect of bortezomib on EGFR expression in head and neck squamous cell carcinoma cell lines. Anticancer Res 28:687–692PubMedGoogle Scholar
  28. Yang Y, Ikezoe T, Saito T, Kobayashi M, Koeffler HP, Taguchi H (2004) Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling. Cancer Sci 95:176–180. doi:10.1111/j.1349-7006.2004.tb03200.x PubMedCrossRefGoogle Scholar
  29. Zhu Z (2007) Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives. Acta Pharmacol Sin 28:1476–1493. doi:10.1111/j.1745-7254.2007.00681.x PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Jens Wagenblast
    • 1
  • Mehran Baghi
    • 1
  • Christoph Arnoldner
    • 1
  • Sotirios Bisdas
    • 1
  • Wolfgang Gstöttner
    • 1
  • Hanns Ackermann
    • 2
  • Angelika May
    • 1
  • Markus Hambek
    • 1
  • Rainald Knecht
    • 1
  1. 1.ENT DepartmentFrankfurt University Medical School, University HospitalFrankfurt/MainGermany
  2. 2.Department for Biometry and Statistical AnalysisFrankfurt University Medical SchoolFrankfurt/MainGermany

Personalised recommendations